



## Clinical trial results:

**A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent**

### Summary

EudraCT number	2014-003625-17
Trial protocol	DE ES BE SE CZ FI PL IT
Global end of trial date	12 November 2021

### Results information

Result version number	v1 (current)
This version publication date	27 October 2022
First version publication date	27 October 2022

### Trial information

#### Trial identification

Sponsor protocol code	CA209-275
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussee de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 February 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 November 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To estimate ORR based on blinded independent review committee (BIRC) assessments (using RECIST 1.1) of nivolumab monotherapy in subjects with tumor expressing PD-L1 and overall treated subjects with metastatic or surgically unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Belgium: 7
Country: Number of subjects enrolled	Czechia: 3
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	Germany: 45
Country: Number of subjects enrolled	Italy: 34
Country: Number of subjects enrolled	Japan: 23
Country: Number of subjects enrolled	Poland: 11
Country: Number of subjects enrolled	Spain: 27
Country: Number of subjects enrolled	Sweden: 5
Country: Number of subjects enrolled	United States: 106
Worldwide total number of subjects	270
EEA total number of subjects	135

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	122
From 65 to 84 years	145
85 years and over	3

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

270 participants were treated.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Nivolumab 3 mg/kg
------------------	-------------------

Arm description:

Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Nivolumab 3 mg/kg

Number of subjects in period 1	Nivolumab 3 mg/kg
Started	270
Completed	0
Not completed	270
Adverse event, serious fatal	1
Poor/Non-Compliance	1
Subject Withdrew Consent	5
Other Reasons	5
Participant Request to Discontinue Treatment	20
Adverse Event Unrelated to Study Drug	39
Study Drug Toxicity	31
Lost to follow-up	1
Disease Progression	167



## Baseline characteristics

### Reporting groups

Reporting group title	Nivolumab 3 mg/kg
-----------------------	-------------------

Reporting group description:

Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W

Reporting group values	Nivolumab 3 mg/kg	Total	
Number of subjects	270	270	
Age categorical			
Units: Subjects			
Adults (18-64 years)	122	122	
From 65-84 years	145	145	
85 years and over	3	3	
Age Continuous			
Units: Years			
arithmetic mean	65.0		
standard deviation	± 9.38	-	
Sex: Female, Male			
Units:			
Female	59	59	
Male	211	211	
Race/Ethnicity, Customized			
Units: Subjects			
Asian	30	30	
White	231	231	
Black or African American	2	2	
American Indian or Alaska Native	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Other	3	3	
Not Reported	4	4	
Ethnicity (NIH/OMB)			
Units: Subjects			
Not Hispanic or Latino	156	156	
Hispanic or Latino	2	2	
Unknown or Not Reported	112	112	

## End points

### End points reporting groups

Reporting group title	Nivolumab 3 mg/kg
Reporting group description:	
Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W	

### Primary: Objective Response Rate per BIRC Assessment

End point title	Objective Response Rate per BIRC Assessment <sup>[1]</sup>
End point description:	
Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee	
End point type	Primary
End point timeframe:	
From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (assessed up to 14 months)	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Only summary statistics were planned for this endpoint	

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	265			
Units: Percent of participants				
number (confidence interval 95%)	19.6 (15.0 to 24.9)			

### Statistical analyses

No statistical analyses for this end point

### Primary: ORR per BIRC Assessment by PD-L1 expression level

End point title	ORR per BIRC Assessment by PD-L1 expression level <sup>[2]</sup>
End point description:	
Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee PD-L1 expression level= membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells. n = Number of participants in each category	
End point type	Primary

End point timeframe:

From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (assessed up to 14 months)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	265			
Units: Percent of Participants				
number (confidence interval 95%)				
PD-L1 <1%	16.1 (10.5 to 23.1)			
PD-L1 >= 1%	23.8 (16.5 to 32.3)			
PD-L1 <5%	15.8 (10.8 to 21.8)			
PD-L1 >=5%	28.4 (18.9 to 39.5)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Duration of Response (DOR)

End point title	Duration of Response (DOR) <sup>[3]</sup>
-----------------	---

End point description:

DOR is defined as the time from first confirmed response, complete response (CR) or partial response (PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who start subsequent therapy without a prior reported progression will be censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment.

"99999"=N/A

End point type	Primary
----------------	---------

End point timeframe:

From the first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurs first (up to approximately 14 months)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: Months				
median (confidence interval 95%)	99999 (7.43 to 99999)			



## Statistical analyses

No statistical analyses for this end point

### Primary: Time to Response (TTR)

End point title	Time to Response (TTR) <sup>[4]</sup>
-----------------	---------------------------------------

End point description:

TTR is defined as the time from first dosing date to the date of the first confirmed complete response (CR) or partial response (PR), as assessed by the Blinded Independent Review Committee (BIRC). Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

End point type	Primary
----------------	---------

End point timeframe:

From first dosing date to the date of the first confirmed response (up to approximately 14 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: Months				
median (full range (min-max))	1.87 (1.6 to 5.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Objective Response Rate (ORR) per Investigator

End point title	Objective Response Rate (ORR) per Investigator
-----------------	--

End point description:

Investigator-assessed ORR was defined as the percent of participants with a best overall response of confirmed complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD-L1 expression level = Membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.

End point type	Secondary
----------------	-----------

End point timeframe:

From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (up to approximately 45 months)

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	270			
Units: Percent of Participants				
number (confidence interval 95%)				
All treated participants	24.8 (19.8 to 30.4)			
PD-L1 <1%	19.9 (13.7 to 27.3)			
PD-L1 ≥ 1%	30.6 (22.7 to 39.6)			
PD-L1 <5%	20.9 (15.3 to 27.4)			
PD-L1 ≥5%	33.7 (23.7 to 44.9)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
Overall Survival was defined as the time from first dosing date to the date of death. A participant who had not died was censored at last known date alive. PD-L1 expression level = membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.	
End point type	Secondary
End point timeframe:	
From first dosing date to the date of death (up to approximately 23 months)	

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	270			
Units: Months				
median (confidence interval 95%)				
All treated participants	8.57 (6.05 to 11.27)			
PD-L1 <1%	5.95 (4.37 to 8.08)			
PD-L1 ≥ 1%	11.86 (9.10 to 19.12)			
PD-L1 <5%	6.24 (4.96 to 9.00)			
PD-L1 ≥5%	13.54 (9.63 to 22.14)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
-----------------	---------------------------------

End point description:

PFS was defined as the time from first dosing date to the date of the first documented tumor progression, based on Blinded Independent Review Committee (BIRC) assessments or death due to any cause. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PD-L1 expression level is defined as membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dosing date to the date of the first documented tumor progression (up to approximately 6 months)

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	270			
Units: Months				
median (confidence interval 95%)				
All treated participants	1.94 (1.87 to 2.33)			
PD-L1 <1%	1.87 (1.74 to 2.00)			
PD-L1 >= 1%	3.45 (1.91 to 3.71)			
PD-L1 <5%	1.87 (1.81 to 2.04)			
PD-L1 >=5%	3.68 (1.91 to 5.52)			

## Statistical analyses

No statistical analyses for this end point

### Post-hoc: Duration of Response (DOR) - Extended Collection

End point title	Duration of Response (DOR) - Extended Collection
-----------------	--

End point description:

DOR is the time from first confirmed response, complete (CR) or partial response (PR) to the date of the first tumor progression PER RECIST 1.1 criteria or death due to any cause, whichever occurs first.

Participants without prior reported progression will be censored at the last evaluable tumor assessments prior to subsequent anticancer therapy. Participants who die without a reported prior progression will be considered on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date.

End point type	Post-hoc
----------------	----------

End point timeframe:

From the first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurs first (up to approximately 32 months)

<b>End point values</b>	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	56			
Units: Months				
median (confidence interval 95%)	20.27 (11.50 to 31.31)			

## Statistical analyses

No statistical analyses for this end point

## Post-hoc: Time to Response (TTR) - Extended Collection

End point title	Time to Response (TTR) - Extended Collection
-----------------	--

End point description:

TTR is defined as the time from first dosing date to the date of the first confirmed complete response (CR) or partial response (PR), as assessed by the Blinded Independent Review Committee (BIRC). Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date.

End point type	Post-hoc
----------------	----------

End point timeframe:

From first dosing date to the date of the first confirmed response (up to approximately 14 months)

<b>End point values</b>	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	56			
Units: Months				
median (full range (min-max))	1.97 (1.6 to 13.8)			

## Statistical analyses

No statistical analyses for this end point

## Post-hoc: Objective Response Rate (ORR) per BIRC Assessment - Extended Collection

End point title	Objective Response Rate (ORR) per BIRC Assessment - Extended Collection
-----------------	---

End point description:

Objective Response Rate (ORR) was defined as the percent of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria). RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee PD-L1 expression level= membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.

Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date."

End point type	Post-hoc
----------------	----------

End point timeframe:

From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (up approximately to 43 months)

End point values	Nivolumab 3 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	270			
Units: Percent of Participants				
number (confidence interval 95%)				
All treated participants	20.7 (16.1 to 26.1)			
PD-L1 <1%	16.4 (10.8 to 23.5)			
PD-L1 >= 1%	25.8 (18.4 to 34.4)			
PD-L1 <5%	16.0 (11.1 to 22.1)			
PD-L1 >=5%	31.3 (21.6 to 42.4)			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Participants were assessed for all-cause mortality from their first dose to study completion, (up to approximately 80 months).

SAEs and NSAEs were assessed from first dose to 100 days following last dose (up to approximately 78 months).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	24.1

### Reporting groups

Reporting group title	Nivolumab 3 mg/kg
-----------------------	-------------------

Reporting group description:

Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W

Serious adverse events	Nivolumab 3 mg/kg		
Total subjects affected by serious adverse events			
subjects affected / exposed	199 / 270 (73.70%)		
number of deaths (all causes)	225		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm progression			
subjects affected / exposed	95 / 270 (35.19%)		
occurrences causally related to treatment / all	0 / 100		
deaths causally related to treatment / all	0 / 89		
Metastases to bone			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases to central nervous system			

subjects affected / exposed	4 / 270 (1.48%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Metastases to lung				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Transitional cell cancer of renal pelvis and ureter metastatic				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Transitional cell carcinoma				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Tumour associated fever				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Tumour pain				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Adenocarcinoma pancreas				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma recurrent				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bladder neoplasm				

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Arteriovenous fistula			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Circulatory collapse			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Hypertension			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Shock haemorrhagic			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Superior vena cava syndrome			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arteriosclerosis			



subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hypotension			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombosis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Obstruction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General physical health deterioration			
subjects affected / exposed	12 / 270 (4.44%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 10		
Fatigue			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			

subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Pyrexia			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	5 / 270 (1.85%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Malaise			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Disease progression			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Mass			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic mass			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sudden death			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	5 / 270 (1.85%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Interstitial lung disease			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	7 / 270 (2.59%)		
occurrences causally related to treatment / all	8 / 8		
deaths causally related to treatment / all	1 / 1		
Pleural effusion			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory failure			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	1 / 2		
Haemoptysis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device dislocation			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombosis in device			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood bilirubin increased			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	1 / 1		

Lipase increased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Quality of life decreased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Liver function test increased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Transaminases increased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Influenza A virus test positive			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Platelet count decreased			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Infusion related reaction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar vertebral fracture			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic fracture			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial flutter			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardio-respiratory arrest			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pericarditis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiovascular disorder			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aortic valve stenosis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypertensive heart disease			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nervous system disorders			
Brain oedema			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebellar haematoma			

subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cerebral disorder				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Monoplegia				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Epilepsy				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Cerebrovascular accident				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Paraesthesia				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Presyncope				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Spinal cord compression				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Syncope				



subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral infarction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Agranulocytosis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Uveitis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		

Colitis				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Duodenitis				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	7 / 270 (2.59%)			
occurrences causally related to treatment / all	5 / 9			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Enteritis				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematemesis				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	4 / 270 (1.48%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Intestinal perforation				

subjects affected / exposed	3 / 270 (1.11%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 2			
Nausea				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	4 / 270 (1.48%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 1			
Small intestinal obstruction				
subjects affected / exposed	7 / 270 (2.59%)			
occurrences causally related to treatment / all	0 / 8			
deaths causally related to treatment / all	0 / 3			
Rectal haemorrhage				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Abdominal pain upper				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Autoimmune colitis				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer haemorrhage				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastritis				

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Immune-mediated enterocolitis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Large intestinal obstruction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Hepatic failure			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Biliary obstruction			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Pemphigoid			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Rash pruritic			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Acute kidney injury			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Bladder tamponade			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Urinary tract obstruction			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal impairment			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Renal failure			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Hypophysitis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Synovitis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Arthritis infective			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Bronchitis				
subjects affected / exposed	2 / 270 (0.74%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Candida infection				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Escherichia urinary tract infection				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	6 / 270 (2.22%)			
occurrences causally related to treatment / all	1 / 6			
deaths causally related to treatment / all	0 / 0			
Stoma site cellulitis				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Staphylococcal infection				
subjects affected / exposed	1 / 270 (0.37%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Septic shock				

subjects affected / exposed	4 / 270 (1.48%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	1 / 1		
Sepsis			
subjects affected / exposed	12 / 270 (4.44%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 4		
Urinary tract infection			
subjects affected / exposed	17 / 270 (6.30%)		
occurrences causally related to treatment / all	0 / 18		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	3 / 270 (1.11%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Anal abscess			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bacterial infection			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Endocarditis			



subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Coronavirus infection			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Kidney infection			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infected lymphocele			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			

subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia			
subjects affected / exposed	2 / 270 (0.74%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Hyperkalaemia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolic acidosis			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypervolaemia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 270 (0.37%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Nivolumab 3 mg/kg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	245 / 270 (90.74%)		
Vascular disorders			
Hypotension			
subjects affected / exposed	17 / 270 (6.30%)		
occurrences (all)	17		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	43 / 270 (15.93%)		
occurrences (all)	50		
Pyrexia			
subjects affected / exposed	65 / 270 (24.07%)		
occurrences (all)	85		
Oedema peripheral			
subjects affected / exposed	45 / 270 (16.67%)		
occurrences (all)	53		
Fatigue			
subjects affected / exposed	97 / 270 (35.93%)		
occurrences (all)	115		
Chills			
subjects affected / exposed	22 / 270 (8.15%)		
occurrences (all)	26		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	59 / 270 (21.85%)		
occurrences (all)	75		
Dyspnoea			
subjects affected / exposed	45 / 270 (16.67%)		
occurrences (all)	53		
Pneumonitis			
subjects affected / exposed	15 / 270 (5.56%)		
occurrences (all)	18		
Psychiatric disorders			

Anxiety subjects affected / exposed occurrences (all)	17 / 270 (6.30%) 18		
Insomnia subjects affected / exposed occurrences (all)	29 / 270 (10.74%) 30		
Investigations Blood creatinine increased subjects affected / exposed occurrences (all)	24 / 270 (8.89%) 31		
Weight decreased subjects affected / exposed occurrences (all)	24 / 270 (8.89%) 25		
Amylase increased subjects affected / exposed occurrences (all)	20 / 270 (7.41%) 35		
Lipase increased subjects affected / exposed occurrences (all)	18 / 270 (6.67%) 37		
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	14 / 270 (5.19%) 15		
Nervous system disorders Headache subjects affected / exposed occurrences (all)	20 / 270 (7.41%) 59		
Dizziness subjects affected / exposed occurrences (all)	21 / 270 (7.78%) 27		
Paraesthesia subjects affected / exposed occurrences (all)	14 / 270 (5.19%) 14		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	58 / 270 (21.48%) 72		
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	60 / 270 (22.22%)		
occurrences (all)	111		
Constipation			
subjects affected / exposed	60 / 270 (22.22%)		
occurrences (all)	74		
Abdominal pain			
subjects affected / exposed	34 / 270 (12.59%)		
occurrences (all)	39		
Vomiting			
subjects affected / exposed	42 / 270 (15.56%)		
occurrences (all)	54		
Nausea			
subjects affected / exposed	71 / 270 (26.30%)		
occurrences (all)	93		
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	45 / 270 (16.67%)		
occurrences (all)	69		
Rash			
subjects affected / exposed	46 / 270 (17.04%)		
occurrences (all)	60		
Dry skin			
subjects affected / exposed	16 / 270 (5.93%)		
occurrences (all)	16		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	22 / 270 (8.15%)		
occurrences (all)	31		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	32 / 270 (11.85%)		
occurrences (all)	32		
Musculoskeletal and connective tissue disorders			
Pain in extremity			

subjects affected / exposed	25 / 270 (9.26%)		
occurrences (all)	27		
Myalgia			
subjects affected / exposed	20 / 270 (7.41%)		
occurrences (all)	23		
Back pain			
subjects affected / exposed	41 / 270 (15.19%)		
occurrences (all)	48		
Arthralgia			
subjects affected / exposed	40 / 270 (14.81%)		
occurrences (all)	52		
Bone pain			
subjects affected / exposed	14 / 270 (5.19%)		
occurrences (all)	14		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	43 / 270 (15.93%)		
occurrences (all)	63		
Upper respiratory tract infection			
subjects affected / exposed	20 / 270 (7.41%)		
occurrences (all)	29		
Nasopharyngitis			
subjects affected / exposed	16 / 270 (5.93%)		
occurrences (all)	20		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	74 / 270 (27.41%)		
occurrences (all)	78		
Dehydration			
subjects affected / exposed	21 / 270 (7.78%)		
occurrences (all)	25		
Hypokalaemia			
subjects affected / exposed	15 / 270 (5.56%)		
occurrences (all)	16		
Hyperglycaemia			

subjects affected / exposed	16 / 270 (5.93%)		
occurrences (all)	24		
Hyponatraemia			
subjects affected / exposed	19 / 270 (7.04%)		
occurrences (all)	22		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 December 2014	Added amylase and lipase; Changed the timing of EORTC QLQ-C30 & EQ-5D to: Assessed following enrollment but prior to dosing on Day 1 and then at every 4th cycle up to 48 weeks, then every 6th cycle until disease progression or treatment is discontinued (whichever occurs later); Synopsis, Secondary Objectives third bullet changed to $\geq 1\%$ .
19 March 2015	Changed the definition of PD-L1 positivity from $\geq 1\%$ to $\geq 5\%$ membranous staining in tumor cells and increased the minimum of PD-L1 positive subjects from 58 to 70. Reduced the Creatinine Clearance (CrCl) threshold in the inclusion criteria from $\geq 40$ mL/min to $\geq 30$ mL/min. Other items have been updated such as; the medical monitor, SAE reporting timeframes and collection timeframes, statistical considerations regarding sample size, and general protocol clarifications.
26 August 2015	Added Objective Response Rate (ORR) as a co-primary objective. Extended subject enrollment in Japan. Other items have been updated such as the medical monitor, statistical considerations regarding the PD-L1 tumor expression and extended enrollment in Japan, and general protocol clarifications.
22 February 2016	Clarified that subjects in Japan, who started treatment after last patient first treatment date of subjects who were enrolled before closure of global enrollment, will not be included in the efficacy analysis. Additionally, other items have been updated, change to the study's Medical Monitor, new fax number for the Study Director, correction to a footnote in table 5.6.2.6-1.
30 September 2016	Provided reference to the newly-updated Investigator Brochure, Version 15.0 in order to ensure the latest safety information is available. Updated Inclusion Criteria contraception requirements. Dose delay criteria updated to add clarification that if treatment is delayed $> 6$ weeks from the last dose, the subject must be permanently discontinued from study therapy. dose delay criteria concerning drug-related Creatinine, AST, ALT and/or Total bilirubin abnormalities is changed to require dose delay for subject with Grade 2 and discontinuation with Grade $\geq 3$ abnormalities regardless baseline. Criteria to Resume Treatment is changed concerning drug-related AST, ALT and/or total bilirubin abnormalities to allow subject with Grade 2 to resume dose when the values return to baseline and management with corticosteroids, if needed, is complete. Discontinuation Criteria is changed concerning drug related AST, ALT and/or Total bilirubin abnormalities to require that subject with Grade $\geq 3$ abnormality or concurrent AST/ALT $> 3 \times$ ULN and total bilirubin $> 2 \times$ ULN should be permanently discontinued. Safety Assessment is changed to clarify requirements on physical examination at visits. Management Algorithms is changed to provide latest guidance per the latest version of the Nivolumab IB.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats



None reported